Introduction
Members of the vascular endothelial growth factor (VEGF) family, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor, regulate various aspects of blood vascular and lymphatic growth and function. VEGF-A acts through the tyrosine kinase receptors VEGFR2 (encoded by KDR/Flk-1) and VEGFR1 (encoded by Flt-1), which mediate signals that are essential for vasculogenesis and angiogenesis. VEGF-C and VEGF-D bind to VEGFR2 and VEGFR3 (encoded by , and mediate signals to vascular and lymphatic endothelial cells (ECs).
1 VEGF-C is expressed in various human cancers, [1] [2] [3] and promotes spread of metastases through induction of angiogenesis and lymphangiogenesis. [4] [5] [6] Metastatic spread of tumors is also observed by overexpression of VEGF-D through induction of lymphangiogenesis. 7 In VEGF-C -/-mice, ECs committed to the lymphatic lineage do not sprout to form lymph vessels, resulting in prenatal death due to the accumulation of fluid in tissues. 8 Of the three VEGF receptors, VEGFR1 is expressed solely on vascular endothelial cells, 9 VEGFR2 is found on both vascular and lymphatic endothelial cells, 10 and VEGFR3 is expressed mainly on lymphatic endothelial cells. 11 Two splice variants of human VEGFR3 have been identified; the short form of which lacks 65 amino acids found in the cytoplasmic tail of the long form. [12] [13] [14] Activation of VEGFR3 leads to protein kinase C-dependent activation of extracellular signal-related kinase (Erk)-1 and -2, and activation of protein kinase B/Akt, which support cell proliferation and survival, respectively. 10 The VEGFR3 -/-embryos die at embryonic day 9.5 due to accumulation of fluid in the pericardial cavity resulting in cardiovascular failure. 15 Missense point mutations in one VEGFR3 allele result in inactivation of tyrosine kinase activity and chronic lymphedema. 16 Moreover, overexpression of a soluble form of VEGFR3
(VEGFR3-Ig) in mouse skin leads to regression of lymph vessels and development of lymphedema, without any apparent effects on the blood vasculature. 17 For personal use only. on . by guest www.bloodjournal.org From 
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In adult humans, circulating endothelial precursor cells may be recruited from the stem cell reservoirs to the peripheral circulation, and play a critical role in postnatal angiogenesis. 18 carboxyl-terminal tyrosine residues by VEGFR2. 23 Moreover, heterodimer between VEGFR1 and VEGFR2 has been reported to be induced by VEGF-A and placental growth factor. 24 These observations suggest that the inter-and intramolecular VEGFR cross-talk is likely to be important in amplification of each signal transduction pathway through phosphorylation of tyrosine residues.
In the present study, we introduced VEGFR3 cDNA into ES cells, and investigated the roles of VEGFR3 signaling in the differentiation of VEGFR2 + vascular progenitor cells into ECs using the system established by Yamashita et al. 20 Our findings suggest that VEGFR3 heterodimerizes with VEGFR2 in the ECs and stimulates VEGFR2 signaling induced by VEGF-C. In addition, the VEGFR3 kinase-negative mutants inhibit the differentiation of vascular progenitor cells into ECs by VEGF-C, suggesting that the VEGFR3 mutants may affect the VEGFR2 signaling pathway through the formation of a VEGFR2-VEGFR3 mutant heterodimer. Thus, VEGFR3 signaling alone is not sufficient to induce the differentiation of mouse ES cells into ECs, but that the coordinated action of VEGFR2 and VEGFR3 is required for this process. In addition, we found that VEGFR3 signaling induced the expression of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) in ECs derived from mouse ES cells, suggesting that VEGFR3 signaling may confer lymphatic endothelial-like phenotypes to
ECs.
Materials and methods
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DNA constructs
Human VEGFR3 (long and short forms) cDNAs were cloned from human embryonic kidney (HEK) 293 cells by polymerase chain reaction (PCR). Unless specifically described, the short form of VEGFR3 was used in the present study. Tyrosine kinase-negative mutants of VEGFR3 (R857R and R1041P) reported by Karkkainen et al. 16 were generated by a PCR-based method. These cDNAs were cloned into the pCAGIP vector, which has a polyoma origin of replication as described previously.
25
Murine VEGF-C cDNA cloned into the pCMV-SPORT6 vector was purchased from
Invitrogen. The VEGF-C(C152S) mutant was generated by a PCR-based method. cDNA for VEGFR2 was kindly provided by L. Claesson-Welsh, and cloned into pcdef3. 
Antibodies

Cell culture
Mouse ES cells, MGZ-5, 25 were maintained in Glasgow minimum essential medium (GMEM, Gibco) supplemented with 10% FBS, 1 mM of sodium pyruvate, 0.2% of 2-mercaptoethanol, 1% of non-essential amino acid solution (Gibco), 1% of penicillin-streptomycin solution (Gibco), 10 3 U/ml of leukemia inhibitory factor (LIF, Chemicon), 10 µg/ml of Zeocin (Invitrogen) and 100 µg/ml of G418 (Gibco). 
Preparation of VEGFs
Human VEGF-A and rat VEGF-C were purchased from R&D Systems and Calbiochem, respectively. VEGF-A and VEGF-C were used at the concentrations of 40 ng/ml and 400 ng/ml, respectively, according to the manufacturer's recommendation. Recombinant VEGF-D (500 ng/ml; R&D Systems) did not significantly activate VEGFR3 (see Figure   1E ); therefore, VEGF-A and C were used in the present study. 
Reverse transcription (RT)-PCR
Total RNA was prepared using Isogen (Nippongene). Reverse transcription was performed with Superscript III (Invitrogen), and PCR was performed using the primers Table 1 .
Immunoprecipitation and immunoblotting
Cells were solubilized in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1.5% Trasylol, and 1 mM phenylmethylsulfonyl fluoride (PMSF).
After clearing by centrifugation, cell lysates were directly subjected to SDS-PAGE, or immunoprecipitated using anti-VEGFR3 or anti-VEGFR2 antibody.
Immunoprecipitates were subjected to SDS-PAGE. Proteins were electrotransferred to PVDF membranes (ProBlott, Applied Biosystems) and subjected to immunoblotting.
Reacted antibodies were detected using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
Hyaluronan (HA) binding assay
HA binding assay was performed as described previously. 26 Differentiated cells were incubated in FITC-conjugated HA (25 µg/ml, Molecular Probes) for 2 hours. Cells were then fixed in 4% formaldehyde, mounted with fluorescent mounting medium and visualized using a fluorescence microscope. The nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole).
Results
Forced expression of VEGFR3 into ES cells stimulates VEGF-C-induced endothelial differentiation
To investigate the roles of VEGFR3 in the endothelial differentiation of VEGFR2 
sVEGF-C(WT) induces the endothelial differentiation of ES cells
VEGF-C is known to activate both VEGFR2 and VEGFR3; however, 400 ng/ml of recombinant VEGF-C failed to phosphorylate VEGFR2 in the present study ( Figure 3A ).
In contrast, VEGF-C (400 ng/ml) induced phosphorylation of VEGFR3, suggesting that higher doses of VEGF-C are required for activation of VEGFR2. We therefore prepared a supernatant of HEK293 cells transfected with wild type VEGF-C cDNA (sVEGF-C(WT)). sVEGF-C(WT) appeared to be more potent than recombinant VEGF-C, and induced phosphorylation of both VEGFR2 and VEGFR3 ( Figure 3A) .
Interestingly, phosphorylation of VEGFR2 was more strongly induced by VEGF-C in the presence, than in the absence, of VEGFR3 ( Figure 3B ), suggesting that VEGF-C induced heterodimer formation and intermolecular cross-activation between VEGFR2
and VEGFR3. Figure S1) , similar to the results using recombinant VEGF-C (Figures 1   and 2 ). These results support the findings that sVEGF-C(WT) stimulates VEGFR2 more potently than the recombinant VEGF-C. We also examined the expression of pan-endothelial marker PECAM-1 in the differentiated ECs by sVEGF-C(WT). The expression levels of VEGFR3 (long and short forms; L and S, respectively) were similar in the cells transfected with the corresponding cDNAs. Figure 3D shows that the expression levels of PECAM-1 were similar in the ECs derived from mock-and VEGFR3 (long and short forms)-transfected VEGFR2 + cells.
Increased expression of LYVE-1 in VEGFR3-transfected ECs
VEGFR3 is known to be important for the differentiation, growth and survival of LECs. 10 In order to examine whether VEGF-C induces differentiation of the VEGFR-2 + cells into LECs, the expression of markers for LECs, LYVE-1, Prox-1 and podoplanin, 29 was measured by semi-quantitative RT-PCR analysis. As shown in Figure 3E , the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From expression of LYVE-1 was increased in both VEGFR3L-and S-transfected cells, but the expression of Prox-1 and podoplanin was not affected.
LYVE-1 is a receptor for the extracellular matrix mucopolysaccharide hyaluronan (HA). 30 We next investigated the binding of HA to ECs. As shown in Figure 3F , the binding of HA was increased in VEGFR3L-or VEGFR3S-transfected ECs. These results suggest that VEGFR3 signaling induces the expression of LYVE-1, and that the long and short forms of VEGFR3 do not confer significant differences in the induction of differentiation of vascular progenitor cells into ECs expressing LYVE-1.
VEGF-C(C152S) fails to induce the differentiation of VEGFR3-transfected VEGFR2 + cells into ECs
VEGF-C(C152S) is known as a selective agonist of VEGFR3. 31 To investigate whether VEGFR3 signaling can compensate for that of VEGFR2 in the process of endothelial cell differentiation, we prepared a supernatant of HEK293 cells transfected with VEGF-C(C152S) cDNA (sVEGF-C(C152S)). Tyrosine phosphorylation of VEGFR3 (L and S) by sVEGF-C(WT) and sVEGF-C(C152S) was similar ( Figure 4A ). Figure 4B shows that mock-and VEGFR3-transfected VEGFR2 + cells were induced to differentiate into ECs by treatment with sVEGF-C(WT), as observed in Figure 3C .
Treatment with sVEGF-C(C152S), however, failed to induce the differentiation of neither mock-nor VEGFR3-transfected VEGFR2 + cells into ECs; instead, these cells differentiated into mural cells. This observation was confirmed by RT-PCR analysis that
showed decreased expression of PECAM-1 and VE-cadherin ( Figure 4C) . Furthermore, the expression of LYVE-1 was restricted to the cells treated with sVEGF-C(WT),
suggesting that LYVE-1 is expressed in ECs, but not in mural cells, in the presence of VEGFR3 signaling. The finding that sVEGF-C(C152S) failed to induce the differentiation of mock-transfected VEGFR2 + cells into ECs confirms that sVEGF-C(C152S) has lost the ability to stimulate VEGFR2. These results indicate that
VEGFR3 signaling alone is not sufficient to induce the differentiation of vascular
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 13 progenitor cells into ECs; instead, VEGFR2 signaling is essential for this process.
Effects of kinase-negative mutants of VEGFR3 on the differentiation of vascular progenitor cells into ECs
Kinase-negative mutants of VEGFR3 (G857R, R1041P) were originally identified in patients with hereditary lymphoedema, a disease that is characterized by swelling of the extremities. 32 We examined the effects of VEGFR3 mutants on the endothelial differentiation of VEGFR2 + cells induced by VEGF-C. As shown in Figure 5A , These findings suggest that VEGFR2 signaling activated by VEGF-C can be blocked dominant negatively by the VEGFR3 mutants.
Discussion
In the present study, we have shown that the transfected VEGFR3 appears to heterodimerize with endogenous VEGFR2 in the ECs and that VEGF-C stimulates VEGFR2 signaling in the presence of VEGFR3. VEGF-C(C152S), which is able to activate VEGFR3 but not VEGFR2, failed to induce the differentiation of mock-and VEGFR3-transfected VEGFR2 + cells into ECs. Moreover, the VEGFR3 kinase-negative mutants inhibited the differentiation of vascular progenitor cells into ECs by VEGF-C,
suggesting that the VEGFR3 mutants may affect the VEGFR2 signaling pathway through the formation of a heterodimer between VEGFR2 and the VEGFR3 mutants. These results suggest that VEGF-C can activate VEGFR2 only at high concentrations, and that VEGFR3 signaling alone is not sufficient to induce the differentiation of vascular progenitor cells into ECs.
Matsumura et al. reported that on OP9 feeder layer, ECs formed packed clusters, while
VEGF-A induced EC dispersion. 33 In contrast, VEGF-C did not induce EC dispersion, but induced morphological changes of ECs, e.g. an elongated spindle-like phenotype.
OP9 cells produce various angiogenic growth factors, including VEGF-A and VEGF-C,
and support the growth of EC cells. Similar to the observation by Matsumura et al. 33 , we found that addition of VEGF-C induced elongated morphology of ECs in the presence as well as in the absence of VEGF-A ( Figure 2B ). VEGFR2 and VEGFR3 may transduce different signaling pathways, and the pathways that induce elongated morphology of ECs may be specifically activated by VEGFR3. There are several papers regarding the morphology of LECs. Makinen et al. 10 reported that LECs show elongated morphology similar to our observation, whereas others did not see any morphological differences between vascular ECs and LECs. 34, 35 These may be due to the differences in culture conditions. We have recently found that human umbilical vein endothelial cells (HUVECs) express high levels of VEGFR3 mRNA and show elongated morphology
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From when they are transfected with Prox-1 cDNA (our unpublished observation). These findings suggest that the morphological alterations in HUVEC may also be induced by the VEGF-C-VEGFR3 signaling pathway.
In humans, but not in mice, VEGFR3 has two spliced variants. 13, 14 In the present study, we found that both forms of VEGFR3 stimulated EC differentiation and the up-regulation of mRNA of LYVE-1, but not of other LEC markers (Figure 3 ). These results suggest that the two spliced variants of VEGFR3 possess similar abilities to stimulate the differentiation of the vascular progenitor cells into ECs via VEGFR2. The long form of VEGFR3, but not the short form, has transforming ability in fibroblasts through the phosphorylation at tyrosine 1337 (Y1337), which is only present in the long form. 36 Shc and Grb2 bind to the phosphorylated Y1337 and regulate the VEGFR3-mediated signal transduction. 37, 38 Therefore, signals induced by the long form of VEGFR3 may be important for oncogene-like activity such as cell proliferation and migration of differentiated LECs, but not for endothelial differentiation.
LYVE-1 is the first lymph-specific HA receptor to be characterized and is involved in HA uptake and transport in lymphatic vessels. 30 HA is an extracellular matrix glycosaminoglycan that plays an important role in maintaining tissue integrity, as well as facilitating the migration of cells during embryonic morphogenesis, inflammation, and wound repair. HA enters the afferent lymphatic vessels and is transported to the draining lymph nodes, where it is degraded before entering the circulation. 39, 40 Therefore, VEGFR3 signaling may determine the function of LECs through the expression of LYVE-1.
Overexpression of the homeobox transcription factor Prox-1 in the blood vascular ECs induced transcription of LEC-specific genes, including VEGFR3, and suppressed the expression of blood vascular EC-specific genes. 41, 42 These findings showed the diversity of endothelial cell phenotypes, and suggested that Prox-1 determines the cell fate of
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ECs to LECs. In the present study, overexpression of VEGFR3 into ES cell-derived vascular progenitor cells stimulated the expression of LYVE-1, but not that of Prox-1 (Figure 3 ). Since Prox-1 has been reported to induce the expression of VEGFR3, the former might act as an upstream component of the latter and confer LEC-like phenotype on ECs during the process of lymphangiogenesis. However, LYVE-1 is expressed in all ECs of the anterior cardinal vein around E9.5, whereas expression of Prox-1 is restricted to a subpopulation of ECs on one side of the vein at this stage, 43 suggesting that expression of LYVE-1 may be regulated by signals other than Prox-1 or VEGF-C.
Moreover, we found that podoplanin was not induced by VEGFR3, suggesting that VEGFR3 signaling alone is not sufficient to induce LECs. Further studies will be required to determine which signals are required for induction of LECs in cooperation with VEGF3 signaling. 
Fig. 4
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Fig. 5
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